CHICAGO — Individuals with KRAS-mutant lung cancer treated with adagrasib experienced significantly prolonged PFS compared with docetaxel, randomized study results presented at ASCO Annual Meeting showed.
The overall response rate with adagrasib demonstrated a significant improvement over docetaxel among adults with previously untreated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, according to researchers.
“These results reinforce [adagrasib] as an efficacious treatment option for patients with KRASG12C-mutated [non-small cell lung cancer] after